SciELO - Scientific Electronic Library Online

 
vol.3 número2Características clínicas de la sepsis en niños internados en el Departamento de Pediatría del Hospital Nacional de Itauguá en el período 2017 al 2018Características de las mujeres diabéticas con síntomas urinarios en el Hospital Nacional de Itauguá índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista científica ciencias de la salud

versión On-line ISSN 2664-2891

Resumen

MONTIEL-JAROLIN, Dora et al. COVID-19 in patients with systemic lupus erythematosus. Rev. cient. cienc. salud [online]. 2021, vol.3, n.2, pp.46-53. ISSN 2664-2891.  https://doi.org/10.53732/rccsalud/03.02.2021.46.

Introduction. Some studies have suggested that hydroxychloroquine has antiviral activity against SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) are frequently treated with hydroxychloroquine, but little is known about the implications of COVID-19 in these patients. Objective. To describe the clinical characteristics of SLE patients diagnosed with COVID-19. Materials and Method. Cros-sectional descriptive study of patients with COVID-19 who consulted at the Hospital Nacional between June 2020 and August 2021. The diagnosis of SLE was established according to the EULAR 2019 criteria. The infection by the SARS-COV-2 virus was confirmed by RT-PCR on the nasopharyngeal swab. Results. Of 350 patients with SLE, 23 (7%) had COVID-19. The COVID-19 patients were between 19 to 58 years of age (median: 38 years), 20 (87%) females. They presented odynophagia 14 (58%), fever 11 (46%), dyspnea 8 (33%), headache 7 (29%), anosmia 4 (17%), ageusia 4 (17%), nasal congestion 4 (17%), diarrhea 3 (13%), 14 (60.9%) other comorbidities. Sixteen patients (70%) were receiving hydroxychloroquine, prednisone 7 (30%), mycophenolate 7 (30%). The disease was critical in 5 (22%) and severe in 2 (9%), 5 (22%) admitted to the ICU and 6 (26%) died. Patients with chronic kidney disease had a higher risk of dying (75% vs 15.8%). There was no difference in mortality between the patients who received or did not receive hydroxychloroquine (18.8% vs 42.9%). Conclusion: Mortality was high. The use of hydroxychloroquine was not a protective factor against death in these patients.

Palabras clave : systemic lupus erythematosus; COVID-19; immunosuppression.

        · resumen en Español     · texto en Español     · Español ( pdf )